Recently discovered through a novel genome-scale T cell activity array, the immune suppressor Siglec-15 which is highly expressed on tumor cells and tumor-infiltrating myeloid cells can serve as a biomarker for predicting the outcomes of anti-PD-1/PD-L1 therapy. Here, PDCD1 is linked to neoplasm.